Amgen Inc. (NASDAQ:AMGN) Given Average Rating of “Hold” by Analysts

Shares of Amgen Inc. (NASDAQ:AMGN) have been assigned a consensus rating of “Hold” from the thirty brokerages that are covering the company, Marketbeat reports. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $354.60.

Several equities research analysts recently commented on AMGN shares. Royal Bank Of Canada boosted their price objective on shares of Amgen from $335.00 to $360.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 4th. TD Cowen restated a “buy” rating on shares of Amgen in a report on Wednesday, February 4th. Guggenheim upped their price target on shares of Amgen from $305.00 to $347.00 and gave the company a “neutral” rating in a report on Friday, February 6th. Leerink Partners reiterated a “market perform” rating and issued a $355.00 price target on shares of Amgen in a research report on Thursday, March 5th. Finally, Wells Fargo & Company raised their price objective on shares of Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a research note on Thursday, March 19th.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Positive cardiovascular data for Amgen’s Repatha: a trial showed a 31% reduction in first major cardiovascular events in a high‑risk population without known significant atherosclerosis — a tailwind for Repatha’s commercial outlook and long‑term revenue potential. Amgen: Repatha Cuts Risk…
• Positive Sentiment: High‑profile media/analyst praise has supported sentiment — Jim Cramer noted Amgen as an attractive large‑cap biotech holding, and Zacks highlighted Amgen’s resilient drug portfolio as offsetting industry headwinds. Those endorsements can boost short‑term demand. Amgen (AMGN) Stock Up Since Jim Cramer Said…
• Positive Sentiment: Zacks analyst commentary reiterates AMGN’s upside from a diversified drug portfolio and steady cash flows, supporting the stock amid sector volatility. The Zacks Analyst Blog Roche Holding, AT&T and Amgen
• Neutral Sentiment: Sector news (other biotech trial readouts and IPO activity) is driving broader health‑care flows but is not specific to Amgen’s fundamentals; watch market‑wide risk appetite. Viridian tumbles on positive data for key eye drug prospect
• Negative Sentiment: FDA safety warning on Tavneos (Amgen’s drug for certain rare autoimmune diseases): regulators identified dozens of drug‑induced liver injury cases (reports cite ~76 cases) and urged close monitoring and prompt discontinuation if liver damage is suspected — a material safety/regulatory overhang that could affect prescribing, labeling, and long‑term sales. US FDA warns of liver injury cases tied to Amgen’s rare disease drug
• Negative Sentiment: Competitive pressure: Teva’s FDA approval of a Prolia (denosumab) biosimilar and other biosimilar filings increase competition in bone‑health markets, which could weigh on Amgen’s Prolia pricing and market share over time. TEVA’s Prolia Biosimilar Gets FDA Nod, Xolair Filing Accepted

Amgen Stock Performance

NASDAQ AMGN opened at $351.85 on Wednesday. The business has a 50 day moving average price of $363.37 and a 200 day moving average price of $331.58. The company has a market capitalization of $189.67 billion, a P/E ratio of 24.73, a PEG ratio of 3.46 and a beta of 0.45. Amgen has a 1-year low of $261.43 and a 1-year high of $391.29. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The company had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.Amgen’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same period in the previous year, the business earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Sell-side analysts expect that Amgen will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is 70.84%.

Hedge Funds Weigh In On Amgen

A number of institutional investors have recently made changes to their positions in the stock. High Note Wealth LLC increased its position in Amgen by 5.8% during the 4th quarter. High Note Wealth LLC now owns 508 shares of the medical research company’s stock worth $166,000 after purchasing an additional 28 shares in the last quarter. TAGStone Capital Inc. lifted its holdings in Amgen by 0.7% in the 4th quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company’s stock valued at $1,351,000 after purchasing an additional 28 shares in the last quarter. Verus Capital Partners LLC boosted its stake in shares of Amgen by 2.3% during the 4th quarter. Verus Capital Partners LLC now owns 1,231 shares of the medical research company’s stock worth $403,000 after purchasing an additional 28 shares during the last quarter. Destination Wealth Management grew its holdings in shares of Amgen by 2.1% during the fourth quarter. Destination Wealth Management now owns 1,393 shares of the medical research company’s stock worth $456,000 after buying an additional 29 shares in the last quarter. Finally, West Family Investments Inc. grew its holdings in shares of Amgen by 1.1% during the third quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock worth $779,000 after buying an additional 30 shares in the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.